Literature DB >> 34989856

Impact of CT-assessed changes in tumor size after neoadjuvant chemotherapy on pathological response and survival of patients with esophageal squamous cell carcinoma.

Sohei Matsumoto1, Kohei Wakatsuki2, Hiroshi Nakade2, Tomohiro Kunishige2, Shintaro Miyao2, Akinori Tsujimoto2, Takanari Tatsumi2, Masayuki Sho2.   

Abstract

PURPOSE: Neoadjuvant chemotherapy (NAC) followed by surgery is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC) in Japan. Computed tomography (CT) is usually used to assess the therapeutic effect of NAC; however, there are no reliable criteria for predicting pathological response or patient prognosis.
METHODS: We included 84 patients who underwent esophagectomy between January 2009 and December 2018 and retrospectively reviewed their CT scans performed before and after NAC. The reduction rate of the largest tumor area (TA), long diameter (LD), and short diameter (SD) were measured on a transverse CT image. The pathological response and cutoff values were calculated using the receiver operating characteristic curve, and the most suitable ones for determining the effect were examined.
RESULTS: The areas under the curve for predicting responders to NAC based on the reduction rate of the TA, LD, and SD were 0.755, 0.761, and 0.781, respectively. The optimal cutoff value of the SD reduction rate for predicting responders to NAC was 22%. An SD reduction ≥ 22% was an independent prognostic factor for overall survival in univariate (p = 0.005, hazard ratio [HR] = 2.755) and multivariate analyses (p = 0.030 HR 2.690). Furthermore, an SD reduction of ≥ 22% was also an independent prognostic factor for relapse-free survival in the univariate (p = 0.007, HR = 2.491) and multivariate analyses (p = 0.007, HR = 0.030).
CONCLUSIONS: The reduction rate of the tumor SD is a simple predictor of pathological response and patient prognosis.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Computed tomography; Esophageal cancer; Neoadjuvant chemotherapy; Prognosis

Mesh:

Year:  2022        PMID: 34989856     DOI: 10.1007/s00423-022-02430-x

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  24 in total

1.  Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy.

Authors:  D R Jones; L A Parker; F C Detterbeck; T M Egan
Journal:  Cancer       Date:  1999-03-01       Impact factor: 6.860

2.  Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma.

Authors:  Hiroki Hara; Makoto Tahara; Hiroyuki Daiko; Ken Kato; Hiroyasu Igaki; Shigenori Kadowaki; Yoichi Tanaka; Yasuo Hamamoto; Hisayuki Matsushita; Michitaka Nagase; Yoshinori Hosoya
Journal:  Cancer Sci       Date:  2013-10-18       Impact factor: 6.716

Review 3.  Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review.

Authors:  Marinke Westerterp; Henderik L van Westreenen; Johannes B Reitsma; Otto S Hoekstra; Jaap Stoker; Paul Fockens; Pieter L Jager; Berthe L F Van Eck-Smit; John T M Plukker; J Jan B van Lanschot; Gerrit W Sloof
Journal:  Radiology       Date:  2005-09       Impact factor: 11.105

4.  Usefulness of computed tomography density of a tumor in predicting the response of advanced esophageal cancer to preoperative chemotherapy.

Authors:  Kohei Wakatsuki; Sohei Matsumoto; Kazuhiro Migita; Masahiro Ito; Tomohiro Kunishige; Hiroshi Nakade; Mitsuhiro Nakatani; Mutsuko Kitano; Masato Takano; Chiho Obayashi; Masayuki Sho
Journal:  Surgery       Date:  2017-07-11       Impact factor: 3.982

5.  CT Signs Can Predict Treatment Response and Long-Term Survival: A Study in Locally Advanced Esophageal Cancer with Preoperative Chemotherapy.

Authors:  Xiao-Yan Zhang; Wan-Pu Yan; Yu Sun; Xiao-Ting Li; Ying Chen; Meng-Ying Fan; Ying Wu; Zhen Liang; Hong-Chao Xiong; Zhi-Long Wang; Ying-Shi Sun; Ke-Neng Chen
Journal:  Ann Surg Oncol       Date:  2015-05-05       Impact factor: 5.344

6.  Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT.

Authors:  J F Griffith; A C Chan; L T Chow; S F Leung; Y H Lam; E Y Liang; S C Chung; C Metreweli
Journal:  Br J Radiol       Date:  1999-07       Impact factor: 3.039

7.  Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.

Authors:  Ken Hatogai; Satoshi Fujii; Takashi Kojima; Hiroyuki Daiko; Tomohiro Kadota; Takeo Fujita; Takayuki Yoshino; Toshihiko Doi; Yuichi Takiguchi; Atsushi Ohtsu
Journal:  J Surg Oncol       Date:  2016-01-12       Impact factor: 3.454

8.  A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).

Authors:  Nobutoshi Ando; Hoichi Kato; Hiroyasu Igaki; Masayuki Shinoda; Soji Ozawa; Hideaki Shimizu; Tsutomu Nakamura; Hiroshi Yabusaki; Norio Aoyama; Akira Kurita; Kenichiro Ikeda; Tatsuo Kanda; Toshimasa Tsujinaka; Kenichi Nakamura; Haruhiko Fukuda
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

9.  Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.

Authors:  D Molena; H H Sun; A S Badr; B Mungo; I S Sarkaria; P S Adusumilli; M S Bains; V W Rusch; D H Ilson; N P Rizk
Journal:  Dis Esophagus       Date:  2013-08-29       Impact factor: 3.429

10.  Worldwide esophageal cancer collaboration.

Authors:  T W Rice; V W Rusch; C Apperson-Hansen; M S Allen; L-Q Chen; J G Hunter; K A Kesler; S Law; T E M R Lerut; C E Reed; J A Salo; W J Scott; S G Swisher; T J Watson; E H Blackstone
Journal:  Dis Esophagus       Date:  2009       Impact factor: 3.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.